Correspondence 0001193125-23-202427 from Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc.
Date: Aug. 3, 2023 · CIK: 0001808898 · Accession: 0001193125-23-202427
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273177
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Jason Drory Re: Benitec Biopharma Inc. Registration Statement on Form S-1, as amended File No. 333-273177
Dear Mr. Drory:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, Benitec Biopharma Inc. hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-273177), as amended, so that it may become effective at 4:30 p.m., Eastern Time on Monday, August 7, 2023, or as soon thereafter as practicable.
Very truly yours,
BENITEC BIOPHARMA INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP BENITEC BIOPHARMA INC. 3940 Trust Way Hayward, California 94545 August 3, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-1004 Attention: Jason Drory Re: Benitec Biopharma Inc. Registration Statement on Form S-1, as amended File No. 333-273177 Dear Mr. Drory: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Benitec Biopharma Inc. hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-273177), as amended, so that it may become effective at 4:30 p.m., Eastern Time on Monday, August 7, 2023, or as soon thereafter as practicable. Very truly yours, BENITEC BIOPHARMA INC. By: /s/ Dr. Jerel Banks Name: Dr. Jerel Banks Title: Chief Executive Officer